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Available online 12 July 2016Inertial cavitation mediated by ultrasound has been previously shown to enable skin permeabilisation for trans-
dermal drug and vaccine delivery, by sequentially applying the ultrasound then the therapeutic in liquid form on
the skin surface. Using a novel hydrogel dosage form, we demonstrate that the use of sub-micron gas-stabilising
polymeric nanoparticles (nanocups) to sustain and promote cavitation activity during simultaneous application
of both drug and vaccine results in a signiﬁcant enhancement of both the dose and penetration of a model vac-
cine, Ovalbumin (OVA), to depths of 500 μm into porcine skin. The nanocups themselves exceeded the penetra-
tion depth of the vaccine (up to 700 μm)due to their small size and capacity to ‘self-propel’. In vivomurine studies
indicated that nanocup-assisted ultrasound transdermal vaccination achieved signiﬁcantly (p b 0.05) higher de-
livery doses without visible skin damage compared to the use of a chemical penetration enhancer. Transdermal
OVA doses of up to 1 μg were achieved in a single 90-second treatment, which was sufﬁcient to trigger an anti-
gen-speciﬁc immune response. Furthermore, ultrasound-assisted vaccine delivery in the presence of nanocups
demonstrated substantially higher speciﬁc anti-OVA IgG antibody levels compared to other transdermal
methods. Further optimisation can lead to a viable, safe and non-invasive delivery platform for vaccineswith po-
tential use in a primary care setting or personalized self-vaccination at home.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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High rates of infectious disease transmission from needle stick inju-
ries have led to 500,000 deaths from Hep B worldwide in 2004 [1]. Ad-
ditionally, the emotional trauma and pain associated with injections
inhibit patient compliance [2]. Thus, increasing widespread recognition
of the disadvantages associated with the use of needles has fuelled re-
search toward non-invasive alternatives. In the context of
immunisation, several safe alternative methods of achieving reliable
and effective vaccination are under development. Transdermal
immunisation (TI) systems in particular have garnered much attention
because of the richly immune-cell-populatedmilieu beneath, ultimately
eliciting effective immune responses in both systemic and mucosal
compartments [3,4]. Such devices also bypass the hepatic/gastrointesti-
nal metabolism that detrimentally alter immune response proﬁle. This
approach involves the application of devices that transiently
permeabilise the stratumcorneum (SC) in order to enable vaccinedeliv-
ery. A range of technologies has been proposed and developed in order
to overcome the barrier presented by the SC to achieve transcutaneous
needle free vaccination, including ballistics-based gene gun devices [5],es, Department of Engineering
Q, UK.
tnagar).
. This is an open access article undermicroneedles [6], iontophoresis [7], chemical enhancers and ultra-
sound-mediated cavitation [8]. This last approach utilises the
shockwaves and microstreaming created by the expansion and violent
collapse of gas bubbles in response to ultrasound exposure and is partic-
ularly attractive because it can be achieved using safe, low-cost technol-
ogy already widely available within healthcare settings [9].
The vast majority of studies exploring the use of ultrasound-mediat-
ed permeabilisation of the skin have demonstrated that inertial cavita-
tion and related mechanisms are effective in increasing the
permeability of the skin to drug and vaccine molecules of around 40
to 70 kDa [8]. Early studies did not use a cavitation nucleation agent,
and involved pre-exposure of the skin to ultrasound followed by appli-
cation of the therapeutic in liquid form on the skin [10–12]. Ultrasound
was thus primarily used as a mechanism to enhance skin
permeabilisation, rather than the active transport of the therapeutic
across the stratum corneum. More recent studies have utilised a simul-
taneous treatment protocol, whereby through the simultaneous appli-
cation of drug solution and ultrasound, a higher dose of the drug is
driven deeper into the skin [8,10].
Recentwork has shown that inertial cavitation nucleated bymicron-
sized talc particles can also promote the active transport of molecules
through a tissue mimicking material (TMM) by simultaneous applica-
tion of ultrasound and model vaccine [13]. Alternative cavitation nuclei
candidates with more clinical translatability include microbubblesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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[14]. However, these candidates are of limited utility for transdermal
delivery due to their rapid depletion and destruction at the skin surface.
Recently, nano-sized cavitation nuclei (nanocups) capable of instigating
and promoting inertial cavitation at modest pressure amplitudes and
frequencies have been developed [15,16]. These particles mediate
sustained cavitation for many minutes, allowing durable exploitation
of inertial cavitation mechanisms. Additionally, their size allows for
higher concentrations of cavitation nuclei particles and therefore higher
intensities of inertial cavitation in a given volume of dosage media.
Nanocups have recently demonstrated enhanced transport of intra-
venously delivered drugs into tumours [15]. The use of nano-cavitation
nuclei in a transdermal delivery system offers exciting potential for vac-
cine delivery, because they can potentially not only be used to enhance
skin permeability but also to mediate the active transport of therapeu-
tics across the stratum corneum without depletion. Here we seek to
demonstrate the utility of nanocups for enhanced ultrasound-mediated
transdermal vaccine delivery, by embedding them alongside (but not
chemically bound to) a model vaccine in a hydrogel formulation that
can also serve as a novel dosage form. This approach enables simulta-
neous application of ultrasound-mediated cavitation with the model
vaccine,making it possible to explore the impact of nanoscale cavitation
events on both skin permeability and active transport of the therapeutic
both ex vivo and in vivo.
2. Methods and materials
2.1. Ex vivo skin source
Porcine skinwas chosen as amodel for human skin based on its sim-
ilarities to human skin in terms of structure, thickness and cellular com-
position [17]. Furthermore, it has similar characteristic impedance
ensuring comparable transmission of ultrasound into the skin [18,19].
Experiments were performed on full thickness porcine skin harvested
from themedial thigh of the animals immediately after abattoir sacriﬁce
(female Landrace pigs, weighing 40–50 kg). Hair on the surface of the
skin was trimmed. Shaving and the use of hair removal chemicals
were not performed to prevent affecting the integrity of the SC. Skin
was then cut into smaller (50 × 50 mm) pieces, wrapped in aluminium
foil and stored in a 4 °C fridge for no longer than 3 days. Prior to an ex-
periment, skin was mounted in a Franz diffusion cell shown in Supple-
mentary Fig. S1.
2.2. Nanocup (NC) cavitation nuclei formulation and characterisation
Nanocups (NCs) are gas-stabilising solid ‘cup’ shaped polymeric
nanoparticles [15]. Brieﬂy they are manufactured in a seed polymerisa-
tion reaction and are composed of a copolymer of hydroxyethylmethyl
methacrylate (HEMA) andmethyl methacrylate (MMA) formed around
and linked to a poly(styrene-co-divinylbenzene) (PS:DVB) copolymer
core (10:1:6 v/v/v ratio of MMA:HEMA:DVB formed around a 300 nm
diameter PS bead). Dynamic light scattering measured the diameter of
NCs to be 460 nm ± 24 nm and the zeta potential as -15 mV ± 1 mV
(n = 10).
2.3. Ex vivo coupling gel formulation
Before formulation within an ultrasound coupling gel [20], model
vaccine and NCs were ﬂuorescently labelled to enable tracking of their
delivery through the skin. OVA (A5503, Sigma-Aldrich, UK) was conju-
gated with FITC dye using the Fluorotag FITC conjugation kit (FITC1,
Sigma-Aldrich, UK). FITC-OVA was then added to each gel (±NC) at a
concentration of 1.5 mg/mL in the gel. NC were labelled with anthra-
cene, (excitation peak 362 nm (UV))/emission peak 407 nm (blue), to
give ﬂuorescent nanocups (F-NCs), and were added to the FITC-OVA
laden gel at a concentration of 5 × 109 NC/mL.SDS PAGE, ﬂuorescence spectroscopy (Luminescence Spectrometer
LS 50B, Perkin Elmer, USA) and dynamic light scattering (Zetasizer
Nano ZS, laser wavelength 633 nm; Malvern Instruments, UK) were
employed to verify OVA stability before and after ultrasound exposure
in the presence and absence of NCs.
2.4. Therapeutic ultrasound setup, exposure parameters and acoustic cavi-
tation detection
A focused ultrasound (FUS) transducer operating at 256 kHz at pres-
sure amplitudes not exceeding 1.5MPawas used to initiate cavitation in
the coupling gel formulation. The FUS system is shown in Supplementa-
ry Fig. S1, and described in the legend to Supplementary Fig. S1 and in
Ref. [13]. Acoustic emissions associated with acoustic cavitation were
recorded throughout exposure using a 5 MHz passive cavitation detec-
tor confocally and co-axially aligned with the FUS transducer [20].
2.5. Electrical resistivity measurement
The comparison of the electrical conductivity of the skin is the cur-
rent gold standard in detection and monitoring of skin permeability in
vitro [21]. In order to determine permeability increases in the skin as a
result of each treatment condition, the electrical resistance of the skin
was used to determine conductivity enhancement ratios, as described
in Tezel et al. [22]. Measurements were taken with PBS in both the
donor and receiver compartments prior to and immediately following
each treatment [23].
2.6. Multi-photon microscopy
Skin samples were imaged using multi-photon microscopy (MPM)
to assess penetration ofﬂuorescently labelled OVA andNCs. Immediate-
ly following ultrasound exposure, the treated skin samples were coated
with ﬂuorescent red 2 μm diameter latex beads (SpheroTech, USA) to
demarcate the skin surface. These 2 μm beads were chosen because
they were too large to diffuse through the skin. Thus the beads acted
as markers for the skin surface to allow visualisation and quantiﬁcation
of the penetration depths of both FITC-OVA and nanocups in the skin. A
modiﬁed BioRad Radiance 2100 MP Multiphoton Microscope (Zeiss;
Jena, Germany), was used for 3D imaging. Near infrared (NIR) laser
beams (λ= 800 nm) were obtained from a tunable 76 MHz femtosec-
ond pulsed Ti:sapphire laser (Mira 900-F, Coherent, Ely, UK) pumped by
a 10Wmultiline argon ion laser (Verdi; Coherent). A Nikon S Fluor 20×
objective (NA = 0.75) was used for all images. The emission wave-
lengths of the ﬁlters selected were: 495 nm (blue), 525 nm (green),
and 595 nm (red). 3 dimensional, 3 colour images were obtained of
XY dimension 389 × 389 μm up to 1.5 mm deep (z-slice resolution
1.95 μm) into each skin sample. 3D representations were generated
from the data acquired using Imaris software (Bitplane, USA). Data
was post processed usingMatlab software (Mathworks, USA). A custom
written algorithm obtained an extrapolated skin surface from the red
beads, and then measured the depths in each column of the 3D image
between this skin surface and every voxel containing FITC-OVA (stained
green) or F-NC (stained blue) to obtain a distribution of depths. The
depth distributionwasweighted according to the ﬂuorescence intensity
of each voxel analysed,with a view to giving the intensity distribution of
the FITC-OVA and F-NCs in eachmeasured area of the skin. Positive con-
trol samples were not imaged due to the denaturation of FITC-OVA by
sodium dodecyl sulphate (SDS), rendering it non-ﬂuorescent.
2.7. In vivo study design
Studies were performed in line with UK Home Ofﬁce legislation. 40
ﬁve-week-old BALB/c female mice were obtained from the Biomedical
Services Unit at the John Radcliffe Hospital (Oxford, UK). Mice were di-
vided into two 20 mice treatment groups consisting of a Delivery and
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tary Fig. S2). The purpose of theDD armwas to examine the penetration
depth and dose of labelled FITC-OVA and F-NCs intomurine skin imme-
diately after treatment, therefore these mice were culled immediately
after treatment. Mice in the IR arm of the study were examined for
the provocation of an immune response as a result of OVA treatment
after 14 days. Blood samples were taken before treatment, and 30 min
after treatment and on days 14 and 35 of the study for detection of
anti-OVA antibodies. In response to the absence of a detectable response
at day 14, a booster treatment was performed on day 21 with increased
concentrations of CpG and OVA (Supplementary Fig. S3). Individual ex-
perimental groups are outlined in Supplementary Table 1.2.8. Coupling preparation
FITC-CpG and unlabelled CpG were obtained from Source Biosci-
ences (Nottingham, UK) and reconstituted in sterile PBS. Coupling gel
was prepared as described except a concentration of 2% was used to
maintain viscosity post-addition of NC and OVA solutions. Deionised ﬁl-
teredwaterwas added to control gel formulations, i.e. those that did not
contain FITC-OVAor F-NCs, to ensure equivalent viscosity. TheOVA con-
centration in all of the formulated gels used on day 0 of each study was
1 mg/mL. OVA and NCs used in the immune response study were un-
tagged to prevent the presence of the dyes affecting the immune re-
sponse. For the booster treatment, lower viscosity gel (0.5%) and
higher OVA (2.5 mg/mL) and CpG dose (30 μg) were used to increase
the possibility of measureable anti-OVA antibody in blood samples.
Gel recipes for each study arm and treatment are shown in Supplemen-
tary Table 2.2.9. In vivo ultrasound setup
A 9 cm2 area at the side of the mouse abdomen was shaved and
depilated 24 h prior to treatment to allow hair removal for effective
sealing of the donor compartment, and time for the skin barrier to re-
cover from the depilatory treatment. Immediately prior to treatment,
the mice were sedated with 2% isoﬂuorane and 98% oxygen (ﬂow
rate: 2 L/min) and the donor compartment was placed onto the skin
surface. 4 mL of the coupling gel formulation was ﬁlled into the donor
compartment and the transducer lowered down onto the mouse to
allow for ultrasound transmission.
Mice in groups 3, 4 and 5 of the DD study, and groups 3 and 5 of the
IR study were subjected to ultrasound treatment for 90 s. The ultra-
sound parameters were 256 kHz frequency, 1MPa peak negative acous-
tic pressure, 10% duty cycle (10 ms on, 90 ms off) at a pulse repetition
frequency of 10 Hz. The ultrasound ﬁeld and focus position within the
donor compartment remained identical to that in the ex vivo setup.
Acoustic emissions were monitored with the same PCD setup in the ex
vivo studies (data given in Supplementary Figs. S4 and S5).2.10. Delivery and distribution study - determination of OVA dose in vivo
Murine skin was excised 6 min after treatment and ﬂash frozen in
liquid nitrogen. Prior to analysis by Enzyme-Linked Immunosorbent
assay (ELISA), skin samples were defrosted and rinsed in ice-cold phos-
phate buffered saline (PBS) (Sigma-Aldrich, UK) to remove blood, and
thenweighed andhomogenised. PBSwas added to the samples at a con-
centration of 1 mL PBS/100 mg skin and homogenised on ice. The
resulting suspension was sonicated on ice with an ultrasonic cell
disruptor (Microson Ultrasonic cell disruptor, Misonix, NY, USA) and
then centrifuged for 5 min at 5000 ×g. The supernatant was removed
and stored at−20 °C until assay. An OVA Enzyme-linked immuno-sor-
bent assay (ELISA) kit (Agro Bio, Germany) was used to quantify levels
of OVA in the tissue homogenate.2.11. Delivery and distribution study - determination of histological dam-
age in vivo
Skin sections from each group were ﬁxed in formalin solution (10%,
ProductHT501128, SigmaAldrich, UK) immediately after harvest. Alter-
nate sections were mounted on slides and stained with H&E to detect
skin damage. Slides were imaged on a Nikon Ti microscope (CFI S
Fluor 40× objective, NA = 0.9).
2.12. Immune response study – determination of OVA-speciﬁc antibody
response
Blood samples (20 μL)were taken from eachmouse on day 0 (before
treatment as a baseline), day 14 (for levels of anti-OVA antibody pro-
duced in response to treatment 1) and day 35 (response to booster
treatment). Blood was diluted in 180 μL PBS (1:10 dilution) and centri-
fuged for 3 min at 3000 rpm. Supernatant was removed and frozen at
−20 °C prior to analysis.
For ELISA, OVAwas diluted to 1 μg/mL and 50 μL of this solution was
added to each well of a Nunc-Immuno Maxisorb ﬂat-bottom 96-well
plate (Fisher Scientiﬁc, UK). The plate was sealed and incubated over-
night at 4 °C. The plate was washed with PBS-Tween (0.5%) 6 times
then blocking performed (5% w/v bovine serum albumin, 50 μL, 1 h,
room temperature (RT)).
Serum samples (1:10 dilution) were diluted further for testing to
1:20 dilution in PBS and 50 μL was added to each well. Each sample
was tested in triplicate and every experimental group contained
serum from at least 3 (n ≥ 3) mice. The samples were sealed and incu-
bated for 1.5 h at RT before the plate was washed (6 times, PBS-
Tween). Goat anti-mouse IgG secondary antibody-HRP (Santa Cruz,
USA) was diluted 1:5000 in PBS and 50 μL added to each well before
1 h incubation at RT. Following incubation, the plate was washed (6
times, PBS-Tween) and 50 μL of TMB substrate (80,091; Alpha Diagnos-
tic International Inc., USA) was added to eachwell and left to develop at
RT for 30min. 50 μL of stop solution (80100; Alpha Diagnostics Interna-
tional Inc., USA) was added to each well. All ELISA plates were read at
absorbance wavelength 450 nm on a FLUOstar Omega plate reader
(BMG Labtech, Germany). The low level of the response generated
prevented a dilution series titration being performed.
3. Results and discussion
3.1. Cavitation-enhanced ex vivo skin permeabilisation
The current gold standard in detection and monitoring of skin per-
meability in vitro is the measurement of electrical resistance of the
skin before and after treatment: as skin is permeabilised, resistance de-
creases. NC in the absence of ultrasound did not change skin conductiv-
ity (Fig. 1A). Non-signiﬁcant (p N 0.05) changes were observed in the
presence of ultrasound and NCs, both with and without OVA. Chemical
permeabilisation using sodium dodecyl sulphate (SDS), in the absence
of ultrasound, showed a signiﬁcant (9.5-fold, p b 0.001) increase in con-
ductivity enhancement.
SDS has been widely studied as a chemical transdermal penetration
enhancer because it is able to readily and reversibly disrupt the barrier
properties of the skin, particularly the SC [24]. Notably, the most sub-
stantial (9.5-fold) increase in skin permeability in this study was ob-
served upon exposure to SDS. However, the main disadvantage of the
use of chemical penetration enhancers is skin irritation due to the dam-
age they cause. In contrast, ultrasound exposure to the skin has not been
observed to cause such damage. Consequently, assuming a suitable de-
livery proﬁle is achievable with the small but observable permeability
change associated with ultrasound skin treatment with NC-gel (either
as a pre-treatment or simultaneously applied with the vaccine), this is
a preferable option to the chemical penetration enhancer.
Fig. 1. (A) Skin conductivity enhancement ratios for each treatment regime. Average values are shown above each data bar. (B) Representative frequency spectrograms of themagnitude
and temporal distribution of broadband acoustic emissions, as detected by the PCD in the coupling gel. (C) Total broadband energy emissions over the entire 90 s (900 pulse) exposure
period, calculated as the sum of the integrals of the ﬁltered Fourier Transforms for each pulse in the exposure. N = 3, standard deviations shown,* denotes p b 0.05, *** denotes
p b 0.005, using ANOVA with Bonferroni analysis to determine statistical differences between groups, n.s. = not signiﬁcant.
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sound-mediated increases in skin permeability aremore effective in the
presence of inertial cavitation [25,26]. Therefore it follows that ultra-
sound coupling gels that favour inertial cavitation events due to the in-
clusion of cavitation nuclei will result in greater skin permeability. This
effect was observed in the current study, where the acoustic emissions
from the ultrasound focus during treatment were quantiﬁed and com-
paredwith increases in permeability. Spectrograms in Fig. 1B give a rep-
resentation of the magnitude (represented by the colour-scale) and
temporal (represented from left to right across the spectrogram) distri-
bution of the frequency content of broadband acoustic emissions as ex-
posures progress. Broadband emissions when the gel did not containany form of cavitation nuclei were sparse and of low magnitude (Fig.
1B(i)), whereas in the presence of NCs, broadband emissions from iner-
tial cavitation were sustained and of high magnitude (Fig. 1B(ii) and
(iii)). The average total emission energy over the exposurewas also sig-
niﬁcantly lower in the absence of NCs (p b 0.001) (Fig. 1C).
The increase in the magnitude of broadband emissions detected in
the presence of NCs is due to nanobubbles on the NC surface [15], acting
as nucleation sites that exclusively promote inertial cavitation [16].
Emissions were sustained due to repeated cavitation events per nano-
particle as well as their replenishment in the focus due to
microstreaming currents set up in the gel. In the absence of NCs, inertial
cavitation events were energetically more difﬁcult to achieve [15].
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MPM is a specialised ﬂuorescence imaging technique that allows
three dimensional imaging of biological tissue to penetration depths
of the order of 1 mm. Skin sections were therefore imaged using MPM
immediately after treatmentwith ultrasound to characterise the degree
and depth of delivery of FITC-OVA and ﬂuorescent NCs into the skin.
Fig. 2 shows qualitative and quantitative results forOVAandNCpen-
etration in the four different treatment groups examined in this study.
3D image representations are shown in row (a) and give a summary
of the difference in delivery for the four treatment conditions. In the ab-
sence of ultrasound treatment, OVA (green) and NCs (blue) penetrated
the skin surface (red) very sparsely, and to a maximum depth of about
100 μm. With the addition of ultrasound treatment but no NC, (Fig. 2A
– application of OVA loaded gel with ultrasound (No NCs)) most of the
drug dose was at the skin surface, with poor penetration beyond. Pre-
treatment with NC in gel and ultrasound before OVA addition, showed
minimal increase in OVA delivery, but considerable NC penetration,
with penetration depths of up to 550 μm (Fig. 2A – NC pre-treatment
with ultrasound). Finally, when OVA was applied simultaneously with
ultrasound and NCs in gel, OVA penetration depth increased substan-
tially to 500 μm, and OVA dose was also markedly increased. NCs in
this group also penetrated to depths of 600–700 μm.Fig. 2. (A) 3D visualisations of OVA andNCpenetration in a single representative sample of each
Each square on the surrounding grid is 100 μm × 100 μm. Ultrasound exposure direction is ve
single representative sample within each treatment group. Shaded regions represent mean ±
overall OVA and NC delivery doses for each treatment group, showing enhancements in do
p b 0.05, ** indicates p b 0.01 and n.s. represents a non-signiﬁcant result.Visual assessment of the MPM images enables qualitative compari-
son of delivery, but does not provide a quantitative assessment of the
OVA and NC penetration achieved in each condition. For this purpose,
Fig. 2B shows histograms of the depths measured for each ﬂuorescent
entity, weighted for pixel intensity to show concentration. Some auto-
ﬂuorescence of collagen was observed in the blue spectrum upon exci-
tation with UV light (excitation/emission range: 270–370 nm/405–
460 nm) [27]. To investigate the extent towhichﬂuorescence emissions
from collagen alone could be visualised in the skin at the microscopy
settings used, the average pixel intensity and meanmaximum penetra-
tion depth of the collagen in untreated skin samples was determined as
8.56 ± 2.04 AU, and 187.96 ± 27.11 μm respectively. To prevent colla-
gen signal being mistaken for NC signal, it was assumed that signal in-
side this intensity and depth in the blue channel could be collagen.
This is represented on each distribution in Fig. 2B. These values were
superimposed on the data and not subtracted because collagen ﬂuores-
cence varies between skin samples, so subtraction of a mean value from
all the samples was inappropriate.
OVA and NC penetration in the absence of ultrasound or NCs was
sparse and shallow – reﬂected by low pixel intensity and poor (up to
150 μm) penetration depth, (Fig. 2B(i) and (ii)). Pre-treatment with ul-
trasound and NC-enriched gel resulted in separate distributions of OVA
and NCs (Fig. 2B(iii)), because ultrasound pre-treatment with NC-of the four visualised treatment groups. OVA=green, NCs= blue, and skin surface= red.
rtically down through the images. (B) Quantitative OVA and NC distribution proﬁles for a
1SD of signal that may have originated from collagen in the skin rather than NCs. (C)
se delivery relative to the control (n = 3). ANOVA used to compare means *indicates
Fig. 3. OVA dose delivered following 90 s exposure to the skin of BalbC mice. Gel and
exposure conditions as described on x-axis, *, ** and *** represent p values of b0.05, 0.01
and 0.001 respectively using a one way ANOVA with Bonferroni multiple comparisons
tests. n = 4 for each group except the CpG and gel with ultrasound (No OVA) group,
where n = 2.
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to inertially collapsing bubbles on theNC surface. The penetration depth
of liquid OVA applied after permeabilisationwas also enhanced approx-
imately 2-fold, but as OVA penetration was reliant on passive diffusion
rather than cavitation-mediated active transport, it was not able to pen-
etrate as deeply as the NCs, and the peak dose of OVA was seen at
around 150 μm, a distance insufﬁcient to achieve marked interaction
with Langerhans cells [28]. Simultaneous application of OVAwith ultra-
sound and NCs enabled microstreaming mechanisms from inertial cav-
itation activity to provide an active transport mechanism for the OVA
molecules. As a result, substantial dose enhancements (about 2-fold
compared to the ultrasound pre-treatment group) were seen in the
penetration depth of OVA when delivered simultaneously with ultra-
sound application in the presence of NC (Fig. 2C).
Both OVA and NCs showed markedly higher dose and penetration
depth in the OVA/NC loaded gel with ultrasound treatment group
than in the other three treatment groups (Fig. 2B(iv)). OVAdose peaked
at 300 μm, and the peak NC dose was at 400 μm. Penetration depth of
NCs was greater than OVA when ultrasound and cavitation related
transport mechanisms were exploited. The NCs ability to propel them-
selves through tissue in an ultrasound ﬁeld as a nanobubble repeatedly
inertially cavitates on their surface is hypothesised to be responsible for
this effect. Therefore, and in contrast to theOVAmolecules, NC transport
is not reliant upon only microstreaming from inertial cavitation. Such
self-propulsion is not a mechanism applicable to microbubble formula-
tions which are destroyed upon inertial cavitation instigation.
Overall OVA andNCdosewas calculated as the sumof the intensities
of all the green or blue ﬂuorescent voxels in a 3D image stack (Fig. 2C).
Signiﬁcant enhancements in delivery were observed in both mean OVA
and NC dose in the NC/OVA gel with ultrasound treatment group
(OVA = 30-fold, NCs = 12,500-fold) compared to the application of
OVA/NC gel without ultrasound, demonstrating enhanced delivery of
both entities.With NC gel+US pre-treatment, the overall OVA concen-
tration increased 16-fold compared to control, whilst with delivery
where cavitation and OVA were concomitantly applied provided an in-
crease of 30-fold relative to control. At ﬁrst glance, it would thus seem
that active transport during delivery only accounts for a further 2-fold
increase over permeabilisation alone. However, it is worth noting that
no OVA was delivered to depths N250 μm in the pre-treatment group,
whilst the increased concentration delivered by cavitation-enhanced
transport reached depths of up to 550 μm. Cells involved in immune re-
sponse generation are found in the lower layers of the epidermis, at
depths of around 200 μm [28]. Even though there is still a signiﬁcant ad-
vantage of cavitation-enhanced transport during delivery in terms of
overall dose delivered, it is therefore most transformative in terms of
mediating a previously unachievable penetration depth. NC dose and
delivery proﬁle in the cavitation-enhanced ultrasound pre-treatment
groupwas similar to that seen in the simultaneous OVA/NC gel with ul-
trasound treatment group, as from the point of the NCs, they had seen
the same ultrasound conditions and were unaffected by the application
of the OVA.
3.3. Nano-nucleated cavitation enhanced transdermal delivery OVA dose in
vivo
To determine the transdermal vaccine dose in vivo, the ultrasound-
assisted system was modiﬁed and implemented in BALB/C mice (Sup-
plementary Fig. S1), using OVA as a model vaccine and the same F-
NCs used in the ex vivo study. Immediately following treatment, mice
were sacriﬁced and skin from the treatment area excised. Sandwich
ELISA was used to determine the OVA content in the skin homogenate.
In order to remove excess OVA and avoid artiﬁcially high readings,
mouse skin was wiped with a damp paper towel after treatment. Fig. 3
shows the average OVA dose delivered to the skin per 90 s treatment.
The dose delivered to the skin was zero in the group that contained no
OVA, conﬁrming the reliability of the assay. Application of the gel to theskin in the absence of ultrasound showed negligible delivery (8.79 ±
24 ng), that was not statistically different to the no OVA group. Upon
the application of ultrasound but in the absence of cavitation inducing
NC, OVA delivery increased to 108 ± 107 ng, but once again this result
was not statistically different to either of the two previously described
groups. The addition of chemical penetration enhancer pre-treatment in-
creased delivered dose approximately 3-fold, but delivery was highest
(0.887 ± 0.258 μg) in the ultrasound/NC assisted vaccine delivery
group, whichwas substantially (3-fold) and statistically (p b 0.05) higher
than the chemical penetration enhancer group, as well as every other
group tested. Supplementary Fig. S4 shows acoustic emissions as mea-
sured by the PCD for each treatment, and results suggest that delivery
was related to inertial cavitation levels during treatment.
Alternative transdermal vaccine delivery methods have shown sim-
ilar vaccine delivery doses. In a dose sparing OVA study using
microneedles in mice, speciﬁc antibody titers from microneedles after
low dose (1 μg) application were one order of magnitude greater than
subcutaneous injection and two orders ofmagnitude greater than intra-
muscular injection [29], indicating that transdermal delivery of a vac-
cine may represent a more efﬁcient delivery route in terms of
elicitation of a speciﬁc immune response for a given vaccine dose. The
use of ultrasound speciﬁcally as a pretreatment was investigated in a
previous in vivo study showing transdermal delivery of tetanus toxoid
vaccine using low frequency (40 kHz) ultrasound as a pre-treatment
prior to the application of a vaccine loaded patch. However a 2 h pre-
treatment exposure was required in this study to deliver a dose of
1.3 μg. Notably, this approach did generate an immune response compa-
rable to that induced by a 10 μg subcutaneous injection [23], again sug-
gesting the efﬁciency of the transdermal route over subcutaneous
injection.
3.4. Ultrasound-assisted vaccination causes no visible skin damage in vivo
In any proposed transdermal treatment application, the treatment
must not cause irreversible or functional damage to the skin surface to
the point where it is unable to protect the body from incoming patho-
gens. SC integrity was therefore assessed after each treatment in vivo.
Possible causes of skin damage in this experiment included (1) damage
caused bymechanical mechanisms from ultrasound exposure and iner-
tial cavitation, or (2) chemical disruption from agents in the gels or skin
pre-treatment. Fig. 4 shows cross sectional histological sections of
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visualisation of the different skin layers and structures within them.
Panel (a) shows non-treated skin with SC intact and the epidermis
and dermis clearly demarcated for comparison.
Assessment of the damage caused by ultrasound exposure can be
performed by comparing images in panels (c) and (e) to panel (a).
Panel (c) (without ultrasound exposure) shows negligible disrup-
tion. The lack of obvious difference between panels (c) and (e), indi-
cates that ultrasound application did not cause structural damage to
the SC, even in the presence of NC mediated inertial cavitation (Fig.
4E).
Among the currently used transdermal permeability enhancement
modalities, chemical penetration enhancers are known for causing irri-
tation and damage to the skin when used at concentrations exceeding
1–2% w/v. Chemical permeability enhancement is usually performed
with the aim of reducing the barrier properties of the SC, and despite
being reversible in most cases, causes vulnerability to external patho-
gens. Healing time from such chemical insult can also take several
days, leaving the skin vulnerable for a considerable amount of time
[30]. Substantial chemically induced damage to the SC was observed
in this study (Fig. 4F, arrows). Application of SDS to the skin as a pre-
treatment resulted in SC breakdown to the point where itwas no longer
attached to the skin, and in some cases, epidermal detachment occurred
(shown by arrows, Fig. 4F) andmarked redness and skin disruptionwas
present on visual inspection prior to sacriﬁce. SDS concentration in this
studywas 7%, increased in from 1% (w/v) in the ex vivo study because as
well as quantifying the skin damage occurred, the intent was also to
identify the maximum OVA penetration possible in the presence of
major to complete SC disruption. Non ablative ultrasound application
at the parameters selected appeared to do no damage to the SC and re-
sulted in the desired short-term disruption necessary for transdermal
vaccine delivery.Fig. 4. Cross sectional images of Haemotoxylin and Eosin stained histological slides of murine sk
the top downwards onto the skin surface. Key: StCo = stratum corneum, Ep = epidermis, D
Comparison of epidermal thicknesses between treatment groups. *** and ** represent p b 0.003.5. OVA-speciﬁc antibody response from NC-nucleated inertial cavitation-
enhanced transdermal delivery
The aim of the long term in vivo study was to elicit an OVA-speciﬁc
antibody response with the nano-nucleated cavitation-assisted trans-
dermal vaccine delivery system. Antibody response was assessed by a
comparison of the levels of speciﬁc anti-OVA IgG antibodies in mouse
blood before treatment versus after a prime-boost vaccination regimen.
A vaccine boost was administered on day 21 of the study, with a higher
OVA concentration (2.5 mg/mL vs. 1mg/mL), a higher CpG dose (30 μg/
mouse vs. 10 μg/mouse) compared to the primer treatment. Blood was
taken on day 35 to examine anti-OVA antibody levels. A sandwich
ELISA technique was used to quantify levels of anti-OVA IgG in the day
35 serum samples, and average absorbance readings (n = 4) for each
treatment group are shown in Fig. 5. In the absence of OVA and/or ultra-
sound, there were no signiﬁcant differences in antibody levels com-
pared to the pre-bleed (non-treated) mice, in accordance with
negligible delivery measured in Fig. 3. Only the chemical penetration
enhancement, the ultrasound-NC assisted transdermal vaccination,
and the subcutaneous injection groups showed signiﬁcantly different
antibody levels to the pre-bleed mice, demonstrating the delivery mea-
sured in Fig. 3 could generate an immune response. In this study, subcu-
taneous injection was used as the positive control, and illustrates the
antibody response at 100% dose delivery. Notably, the ultrasound/NC
assisted system outperformed the chemical penetration enhancer
group.
3.6. Future system development
The present work represents a proof-of-concept study that demon-
strates the potential utility of ultrasound-mediated skin
permeabilisation and molecular transport for transdermal vaccinein after each of the treatment regimens tested. In all images, ultrasound was applied from
e = dermis, Ad = adipose tissue, HaFo = hair follicle, SeGl = sebaceous gland. (Left)
1 and p b 0.01 respectively in one way ANOVA.
Fig. 5. Anti-OVA IgG antibody levels in all of the treatment groups on day 35 of the study.
Micewere bled and serumdiluted in PBS before being applied to a NuncMaxisorp 96well
plate for analysis using a standard anti-OVA ELISA technique as described in methods.
OD = optical density (absorbance). n = 4, standard deviation shown, signiﬁcant
differences determined by one-way ANOVA Bonferroni multiple comparison tests. ***, **
and * = p b 0.05, 0.01, 0.001 respectively.
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route of delivery in a clinical setting, further development and optimisa-
tion is necessary.
Firstly, vaccine stability for each different vaccine candidate must be
assessed following ultrasound exposure, to ensure that vaccine struc-
ture and function is not adversely affected. In the present work,
methods such as SDS PAGE, ﬂuorescence spectroscopy and ELISA were
employed to verify OVA stability before and after ultrasound exposure
in the presence and absence of NCs. OVA structure and function were
unchanged at the ultrasound parameters tested (Supplementary Fig.
S6).
Despite achieving a signiﬁcantly higher anti-OVA antibody level
than the controls in vivo, the system presented in the current work
was not able to illicit an immune response similar to that achieved by
subcutaneous injection,which is the current gold standard. This is large-
ly due to the low delivery efﬁciency associated to this not fully
optimised delivery system, compared to 100% subcutaneous delivery
resulting from injection. Increases in delivery dose and efﬁciency
could be achieved by the optimisation of ultrasound parameters such
as exposure time and pulse repetition frequency, to maximally exploit
the NC cavitation nuclei and their instigation of inertial cavitation. Fur-
ther optimisation strategies could include redesign of the ultrasound
transducer to increase treatment area, decreasing the thickness of the
vaccine dosage gel layer over the skin to allow themaximal dose of vac-
cine to lie directly above the skin and be ready for molecular transport,
and conjugation of OVA/vaccine to theNCs so that propulsion of theNCs
carry larger doses of the vaccine deeper into the skin.4. Conclusions
Inertial cavitation mediated by ultrasound has been previously
shown to mediate permeabilisation of the skin surface to enhance the
transdermal delivery of drugs and vaccines [8,31–34], typically by ﬁrst
exposing the skin to ultrasound and then applying the therapeutic on
the skin in liquid form. In the present work, we demonstrate that the
use of sub-micron cavitation nuclei to promote and sustain cavitation
activity during simultaneous application of ultrasound and vaccine can
signiﬁcantly enhance both the dose and penetration of a therapeutic
across the skin. This was achieved through the development of a novel
dosage form, namely a hydrogel containing both cavitation-inducingnanocups and the vaccine, which can also be used as a matching layer
between the transducer and the skin.
Three regimeswere initially tested ex vivo using porcine skin and ov-
albumin (OVA) as amodel vaccine. Embedding nanocups (but not OVA)
into the hydrogel and exposing the skin to 90 s of ultrasound, followed
by application of OVA in liquid form, enabled OVA to diffuse to an aver-
age depth of 150 μm (Fig. 2b), with only a very small proportion detect-
ed at up to 250 μm; this result is comparable to previous studies which
have sought to pre-permeablize the SC by ultrasound [27–31]. These
levels and depths of delivery are unlikely to provide an opportunity
for substantial interaction with the Langerhans cells in the epidermis.
Embedding both the cups and OVA in the hydrogel and exposing to
90 s of ultrasound resulted in the active transport of vaccine molecules
to depths of up to 550 μm into the skin, with cups reaching depths of
700 μm.We thus hypothesise that microstreaming associated with the
self-propellingnanocups enables themnot only to permeablize the stra-
tum corneum but also to actively transport the co-administered thera-
peutic deeper into the skin due to their ability to sustain inertial
cavitation activity throughout ultrasound exposure. This phenomenon
has been shown in other studies to improve molecular transport in a
gel [13], and also the transport of drugs into tissue [35].
In vivo testing of the ultrasound assisted transdermal delivery sys-
tem has shown that delivery dose of 1 μg can be achieved to murine
skin in a 90 s treatment, without the use of chemical penetration en-
hancers, and that skin integrity is preserved, in stark contrast to when
chemical penetration enhancers such as SDS are used. Furthermore,
the long term immune response study demonstrated that a detectible
level of OVA speciﬁc antibodieswere detected in themouse serum in re-
sponse to an initial dose+ booster treatment of ultrasound/NC assisted
transdermal vaccination. Following the booster treatment, the ultra-
sound/NC assisted transdermal vaccination system outperformed the
chemical penetration enhancers in terms of eliciting a limited but spe-
ciﬁc anti-OVA response. However, it is clear that this approach is still
dramatically less effective than direct injection which provides guaran-
teed delivery of the dose in its entirety. Efforts are now focused on
optimising gel formulation and ultrasound exposure parameters so
that greater delivery and more robust responses can be achieved. It is
hoped that such optimisationwill help the ﬁeld of transdermal vaccina-
tion progress so that reliable and robust needle free vaccination can be
achieved.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2016.07.016.
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